Psoriasis is a common, chronic, immune-mediated skin disorder that may be complicated by psoriatic arthritis in
up to one-third of patients. Psoriasis treatments are increasingly
effective, yet more expensive, thus requiring rational decision-making on interventional priorities. The ability to perform cost-utility analyses is hindered by the lack of algorithms
that allow the inference of utility measures, like QALY, from specific dermatological health-related qualityof-
life (HR-QoL) measures (e.g. Dermatology Life Quality
Index [DLQI]). This study aimed to assess whether psoriasisrelated
HR-QoL data (DLQI) could be used to obtain utility measures for use in economic analyses
